Shuttle Pharma Finalizes Highly Dilutive $3.5M Offering at Deep Discount, Issuing 7M Shares

summarizeSummary

Shuttle Pharmaceuticals finalized a public offering to raise $3.5 million by selling 2.24 million common shares and 4.76 million pre-funded warrants at a significant discount, leading to substantial potential dilution for existing shareholders.

check_boxKey Events

• Offering Finalized and Priced

  The company is offering 2,238,800 shares of common stock at $0.50 per share and pre-funded warrants to purchase up to 4,761,200 shares at $0.499 per warrant, with an exercise price of $0.001 per share. Total gross proceeds are approximately $3.5 million.

• Deep Discount Pricing

  The offering price of $0.50 per common share is a significant discount compared to the closing price of $0.87 on March 5, 2026, and the current market price of $0.917.

• Substantial Potential Dilution

  The offering could result in the issuance of up to 7,000,000 new shares (common stock plus shares from warrant exercise), representing over 200% of the 3,352,490 shares outstanding as of March 5, 2026.

• Critical Capital Raise for Distressed Company

  This financing is crucial for the company, which reported a working capital deficit of $0.7-$0.8 million as of December 31, 2025, and has a going concern warning from its auditors.

auto_awesomeAnalysis

Shuttle Pharmaceuticals has finalized the terms of its public offering, which was previously announced. The company is raising approximately $3.5 million by selling 2.24 million shares of common stock at $0.50 per share and 4.76 million pre-funded warrants at $0.499 each. This pricing represents a substantial discount to the stock's closing price of $0.87 on March 5, 2026, and today's price of $0.917. The offering introduces a significant number of new securities, with the potential issuance of 7 million shares (common stock plus shares from warrant exercise) compared to 3.35 million shares currently outstanding, indicating over 200% potential dilution. This capital raise is critical for the company, which reported a working capital deficit and has a going concern warning from its auditors. The proceeds are earmarked for marketing expenses and general working capital, following a prior $3.45 million spend on investor relations in 2025. While providing necessary capital, the terms of this offering are highly unfavorable for existing shareholders due to the deep discount and massive dilutive impact.